These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32013873)

  • 1. Epidemiology of acute rubella infection in Zambia during the pre-vaccination period (2005-2016) as a baseline for monitoring rubella epidemiology in the post-rubella vaccine introduction era.
    Mazaba ML; Siziya S; Monze M; Cohen D
    BMC Infect Dis; 2020 Feb; 20(1):101. PubMed ID: 32013873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of rubella virus cases in the pre-vaccination era of Ethiopia, 2009-2015.
    Getahun M; Beyene B; Gallagher K; Ademe A; Teshome B; Tefera M; Asha A; Afework A; Assefa E; HaileMariam Y; HaileGiorgis Y; Ketema H; Shiferaw D; Bekele A; Jima D; Kebede A
    BMC Public Health; 2016 Nov; 16(1):1168. PubMed ID: 27863513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey.
    Hayford K; Mutembo S; Carcelen A; Matakala HK; Munachoonga P; Winter A; Wanyiri JW; Searle K; Mwansa FD; Mwiche A; Phiri C; Book C; Thuma PE; Moss WJ
    Vaccine; 2019 Apr; 37(17):2387-2393. PubMed ID: 30905529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a Measles and Rubella Vaccination Campaign on Seroprevalence in Southern Province, Zambia.
    Carcelen AC; Mutembo S; Matakala KH; Chilumba I; Mulundu G; Monze M; Mwansa FD; Moss WJ; Hayford K
    Am J Trop Med Hyg; 2021 May; 104(6):2229-2232. PubMed ID: 33939639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of rubella infection in Cameroon: a 7-year experience of measles and rubella case-based surveillance, 2008-2014.
    Nimpa Mengouo M; Ndze VN; Baonga F; Kobela M; Wiysonge CS
    BMJ Open; 2017 Apr; 7(4):e012959. PubMed ID: 28389483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ongoing measles and rubella transmission in Georgia, 2004-05: implications for the national and regional elimination efforts.
    Doshi S; Khetsuriani N; Zakhashvili K; Baidoshvili L; Imnadze P; Uzicanin A
    Int J Epidemiol; 2009 Feb; 38(1):182-91. PubMed ID: 19074954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rubella IgM epidemiology in the pre-rubella vaccination era in Uganda.
    Bagenda F; Mulogo EM; Apecu RO; Kisakye A; Opar BT
    BMC Infect Dis; 2020 Mar; 20(1):219. PubMed ID: 32164592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rubella transmission and the risk of congenital rubella syndrome in Liberia: a need to introduce rubella-containing vaccine in the routine immunization program.
    Woyessa AB; Ali MS; Korkpor TK; Tuopileyi R; Kohar HT; Dogba J; Baller A; Monday J; Abdullahi S; Nagbe T; Mulbah G; Kromah M; Sesay J; Yealue K; Nyenswah T; Gebrekidan MZ
    BMC Infect Dis; 2019 Sep; 19(1):813. PubMed ID: 31533658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rubella control in Papua New Guinea: age-specific immunity informs strategies for introduction of rubella vaccine.
    Riddell M; Senn N; Clements CJ; Hobday L; Cowie B; Kurubi J; Kevin A; Siba P; Reeder JC; Morgan C
    Vaccine; 2012 Dec; 30(52):7506-12. PubMed ID: 23103194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congenital Rubella Syndrome Surveillance After Measles Rubella Vaccination Introduction in Yogyakarta, Indonesia.
    Herini ES; Triono A; Iskandar K; Prasetyo A; Nugrahanto AP; Gunadi
    Pediatr Infect Dis J; 2021 Dec; 40(12):1144-1150. PubMed ID: 34609101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in measles and rubella elimination in Iran.
    Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An 11-year trend of rubella incidence cases reported in the measles case-based surveillance system, Ghana.
    Dongdem AZ; Alhassan E; Opare D; Boateng G; Bonsu G; Amponsa-Achiano K; Sarkodie B; Dzotsi E; Adjabeng M; Afagbedzi S; Alhassan Y; Agyabeng K; Asiedu-Bekoe F
    Pan Afr Med J; 2021; 39():132. PubMed ID: 34527148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-specific prevalence of IgG against measles/rubella and the impact of routine and supplementary immunization activities: A multistage random cluster sampling study with mathematical modelling.
    Hachiya M; Vynnycky E; Mori Y; Do HT; Huynh MK; Trinh LH; Nguyen DD; Tran NAT; Hoang TT; Hoang HHT; Vo NDT; Le TH; Ichimura Y; Miyano S; Okawa S; Thandar MM; Yokobori Y; Inoue Y; Mizoue T; Takeda M; Komada K
    Int J Infect Dis; 2024 Jul; 144():107053. PubMed ID: 38641317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.
    Johnson H; Hillary IB; McQuoid G; Gilmer BA
    Vaccine; 1995 Apr; 13(6):533-7. PubMed ID: 7483773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
    Kremer JR; Schneider F; Muller CP
    Vaccine; 2006 Mar; 24(14):2594-601. PubMed ID: 16427163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of impact of measles rubella campaign on vaccination coverage and routine immunization services in Bangladesh.
    Uddin MJ; Adhikary G; Ali MW; Ahmed S; Shamsuzzaman M; Odell C; Hashiguchi L; Lim SS; Alam N
    BMC Infect Dis; 2016 Aug; 16():411. PubMed ID: 27519586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against measles and rubella virus among different age groups in Thailand: A population-based serological survey.
    Wanlapakorn N; Wasitthankasem R; Vichaiwattana P; Auphimai C; Yoocharoen P; Vongpunsawad S; Poovorawan Y
    PLoS One; 2019; 14(11):e0225606. PubMed ID: 31770412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.